Luteolin-7-rutinoside (Synonyms: Luteolin 7-Rutinoside, Luteolin 7-β-Rutinoside, Scolymoside, Skolimoside) |
Katalog-Nr.GC36497 |
Luteolin-7-Rutinosid hat sowohl antiarthritische als auch antimykotische AktivitÄten, kann in einer Kombinationstherapie zur Behandlung von Pilzarthritis aufgrund von C.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 20633-84-5
Sample solution is provided at 25 µL, 10mM.
Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.
At a dose of 10 μg Luteolin-7-rutinoside (lonicerin)/mL, there is an approximately 47% decrease of the proliferation as compared to proliferation of Luteolin-7-rutinoside treated (control) T cells (p<0.05). Luteolin-7-rutinoside at 40 μg/mL dose give almost the same rate of T cell proliferation as does 20 μg/mL dose of Luteolin-7-rutinoside. The suppressive activity is dose dependent. Luteolin-7-rutinoside treatment swifts Th1-Th2 balance away from Th1-toward Th2-type responses. Luteolin-7-rutinoside inhibits nitric oxide (NO) production from macrophages[1].
[1]. Lee JH, et al. Antiarthritic effect of lonicerin on Candida albicans arthritis in mice. Arch Pharm Res. 2011 May;34(5):853-9.
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *